Fig. 5

Low BCAM expression was associated with high immunogenicity; distinct BCAM expression patterns could indicate potential therapeutic strategies in ccRCC. A Immune cell score in the BCAM-low and BCAM-high subgroups. *p < 0.05, **p < 0.01, ***p < 0.001. B The percentage abundance of tumor-infiltrating immune cells in each sample. C The expression of immune checkpoints in the BCAM-low and BCAM-high subgroups. ***p < 0.001. D The association between different immune subgroups and the mRNA and protein expression and methylation level of BCAM, and the proportion of Z-Score > 0 of the 4 immune subgroups in BCAM methylation level, mRNA expression level and protein expression level, respectively. E The expression of angiogenesis-related genes in the BCAM-low and BCAM-high subgroups. *p < 0.05, **p < 0.01, ***p < 0.001. F Tumor Immune Dysfunction and Exclusion (TIDE) score of the BCAM-low and BCAM-high subgroups. G Distribution of Sorafenib, Pazopanib and Axitinib IC50 scores in the BCAM-low and BCAM-high subgroups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001